Medical Device Success
JANUARY 29, 2014
What will you be doing to increase your marketing acumen and ROI in 2014? Marketo – A company that specializes in marketing automation software. Medmarc – An insurance company that specializes in insuring life science companies. Reading time: 4 – 6 minutes. Definitive guides [link]. On demand webinars [link].
pharmaphorum
OCTOBER 24, 2022
Of particular interest to companies, partly because the alternative is few, if any, sales are ‘special’ funds that can allow a company to bring in revenue for a product, even when there are questions about its value. The PPRS changed over time, and the 2014 PPRS first introduced a cap to NHS branded medicines spending delivered via rebates.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 14, 2022
In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very strict process. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.”
Medical Device Success
SEPTEMBER 2, 2013
So, for a medical device salesperson, a strategy could be to “Increase exposure of Product One Touch Cure-All to doctors that specialize in Touchology”. Now that you have your sales team working on a four month plan, it won’t be hard to challenge them to an entire year plan for 2014. . Typically, the best tactics are quantitative.
Pharmaceutical Technology
JANUARY 23, 2023
Out of the seven biologics approved to treat moderate to severe CD in adults, only the anti-TNFαs, Remicade (infliximab), and Humira (adalimumab), have been approved for paediatric patients, with Humira receiving the most recent approval in 2014.
Pharmaceutical Technology
OCTOBER 5, 2022
Between 2009 and 2014, the time period of Biogen’s alleged misconduct, the standard of care for MS involved the use of Biogen’s immunomodulatory drugs such as Avonex (Interferon beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab).
PM360
SEPTEMBER 8, 2023
While there are recent efforts to curb the prices of insulin, GoodRx research 5 shows the average cash price for insulin rose 54% from 2014 to 2019, and only decreased 7.1% In the U.S., diabetes is one of the most common chronic diseases, affecting over 37 million people. from 2020 to 2023. And nearly 1.35
Expert insights. Personalized for you.
100 
Let's personalize your content